Category: obesity

Away day brings programmes together to explore cancer challenges

Posted on by ICEP admin

Bringing researchers from different areas together is vital in sharing expertise and generating opportunities for new collaborations and connections. Last week members of the Integrative Cancer Epidemiology Programme (ICEP) joined colleagues specialising in Mendelian randomization (MR) within the MRC Integrative Epidemiology Unit (IEU), for a day of discussion, networking and sharing their latest research.

Here, Senior Research Fellow Philip Haycock, who leads the Cancer Progression and Drug Target research theme in ICEP, summarises some the day’s discussions and overlapping research. (more…)

EASD 2023: At the interface between diabetes research and clinical practice

Posted on by IEU admin

PhD student Maddy Smith shares what she learned from attending a recent international conference on diabetes research.

An exciting time for metabolic health

Weight loss drugs such as Wegovy and Ozempic have made many headlines and sparked a frenzy on social media in recent months. Not only is their potential to “end obesity” being unpacked in the media, but also their issues such as side effects, weight regain after stopping taking it, and supply shortages. Since obesity is a main risk factor for type 2 diabetes, these new drugs have implications for diabetes treatment – in fact, some of them were originally developed to treat diabetes and weight loss was noticed to be a concurrent effect.

A selection of news headlines about drugs to treat obesity.

 

(more…)

The MRC Integrative Epidemiology Unit at the University of Bristol (IEU) conducts some of the UK's most advanced population health science research. It uses genetics, population data and experimental interventions to look for the underlying causes of chronic disease.